Results 1 to 10 of about 23,453 (154)

Indoleamine 2,3- Dioxygenase: A Novel Immunotherapeutic Target for Osteosarcoma [PDF]

Journal of Cancer and Allied Specialties, 2022
Introduction: Tumour-emitted molecules induce immunosuppression in the tumour microenvironment. An immunosuppressive enzyme, indoleamine 2,3-dioxygenase (IDO/IDO1), facilitates immune escape in several malignant tumours, including osteosarcoma ...
Asim Farooq, Bilal Zulfiqar, Kashif Asghar   +2 more
doaj   +2 more sources

The Two Sides of Indoleamine 2,3-Dioxygenase 2 (IDO2) [PDF]

Cells
Indoleamine 2,3-dioxygenase 1 (IDO1) and IDO2 originated from gene duplication before vertebrate divergence. While IDO1 has a well-defined role in immune regulation, the biological role of IDO2 remains unclear.
Chiara Suvieri, Maria Laura Belladonna, Claudia Volpi   +2 more
doaj   +2 more sources

From Melanoma Development to RNA-Modified Dendritic Cell Vaccines: Highlighting the Lessons From the Past

Frontiers in Immunology, 2021
Although melanoma remains the deadliest skin cancer, the current treatment has not resulted in the desired outcomes. Unlike chemotherapy, immunotherapy has provided more tolerable approaches and revolutionized cancer therapy.
Mahdi Abdoli Shadbad, Mahdi Abdoli Shadbad, Khalil Hajiasgharzadeh, Afshin Derakhshani, Afshin Derakhshani, Nicola Silvestris, Nicola Silvestris, Amir Baghbanzadeh, Vito Racanelli, Behzad Baradaran, Behzad Baradaran   +10 more
doaj   +1 more source

RETRACTED ARTICLE: Kynurenine promotes neonatal heart regeneration by stimulating cardiomyocyte proliferation and cardiac angiogenesis

Nature Communications, 2022
Indoleamine 2,3 dioxygenase-1 (IDO1) catalyzes tryptophan-kynurenine metabolism in many inflammatory and cancer diseases. Of note, acute inflammation that occurs immediately after heart injury is essential for neonatal cardiomyocyte proliferation and ...
Donghong Zhang, Jinfeng Ning, Tharmarajan Ramprasath, Changjiang Yu, Xiaoxu Zheng, Ping Song, Zhonglin Xie, Ming-Hui Zou   +7 more
doaj   +1 more source

Indoleamine 2,3-Dioxygenase 1: A Promising Therapeutic Target in Malignant Tumor

Frontiers in Immunology, 2021
Tumorigenesis is a complex multifactorial and multistep process in which tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade host immune attacks.
Xiaotian Song, Xiaotian Song, Qianqian Si, Qianqian Si, Rui Qi, Rui Qi, Weidan Liu, Miao Li, Miao Li, Mengyue Guo, Mengyue Guo, Lin Wei, Lin Wei, Zhiyan Yao, Zhiyan Yao   +14 more
doaj   +1 more source

Novel Selective IDO1 Inhibitors with Isoxazolo[5,4-d]pyrimidin-4(5H)-one Scaffold

Pharmaceuticals, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in immunomodulation of several pathological conditions, especially cancers. Here we present the synthesis of a series of IDO1 inhibitors with the novel isoxazolo[5,4-d]pyrimidin-4(5H)-one ...
Ana Dolšak, Tomaž Bratkovič, Larisa Mlinarič, Eva Ogorevc, Urban Švajger, Stanislav Gobec, Matej Sova   +6 more
doaj   +1 more source

What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past

Journal of Experimental & Clinical Cancer Research, 2021
Indoleamine 2,3-dioxygenase 1 (IDO1), a monomeric heme-containing enzyme, catalyzes the first and rate-limiting step in the kynurenine pathway of tryptophan metabolism, which plays an important role in immunity and neuronal function.
Yu Yao, Heng Liang, Xin Fang, Shengnan Zhang, Zikang Xing, Lei Shi, Chunxiang Kuang, Barbara Seliger, Qing Yang   +8 more
doaj   +1 more source

Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cells

Haematologica, 2010
Background The immunoregulatory enzyme indoleamine 2,3-dioxygenase, which catalyzes the conversion of tryptophan into kynurenine, is expressed in a significant subset of patients with acute myeloid leukemia, resulting in the inhibition of T-cell ...
Antonio Curti, Sara Trabanelli, Chiara Onofri, Michela Aluigi, Valentina Salvestrini, Darina Ocadlikova, Cecilia Evangelisti, Sergio Rutella, Raimondo De Cristofaro, Emanuela Ottaviani, Michele Baccarani, Roberto M. Lemoli   +11 more
doaj   +1 more source

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

Haematologica, 2008
Indoleamine 2,3-dioxygenase degrades the amino acid tryptophan which is essential for T cells. Tryptophan depletion causes T-cell cycle arrest and solid tumors that express high levels of indoleamine 2,3-dioxygenase can create immune suppression ...
Martine E.D. Chamuleau, Arjan A. van de Loosdrecht, Corine J. Hess, Jeroen J.W.M. Janssen, Adri Zevenbergen, Ruud Delwel, Peter J.M. Valk, Bob Löwenberg, Gert J. Ossenkoppele   +8 more
doaj   +1 more source

Tryptophan-degrading enzymes in tumoral immune resistance

Frontiers in Immunology, 2016
Tryptophan is required for T lymphocyte effector functions. Its degradation is one of the mechanisms selected by tumors to resist immune destruction.
Nicolas van Baren, Nicolas van Baren, Nicolas van Baren, Benoit J Van den Eynde, Benoit J Van den Eynde, Benoit J Van den Eynde   +5 more
doaj   +1 more source